Search Results

You are looking at 31 - 40 of 149 items for :

  • "prostate-specific antigen" x
  • Refine by Access: All x
Clear All
Full access

Counterpoint: Prostate Cancer Life Expectancy Can Not Be Accurately Predicted From Currently Available Tools

Susan A. McCloskey and Michael R. Kuettel

Kattan MW Subong EN . Combination of prostate specific antigen, clinical stage, and Gleason score to predict pathologic stage of localized prostate cancer: a multi-institutional update . JAMA 1997 ; 277 : 1445 – 1451 . 31. Kattan MW

Full access

Biochemical Relapse After Primary Treatment for Prostate Cancer: Studies on Natural History and Therapeutic Considerations

Eli Rosenbaum, Alan Partin, and Mario A. Eisenberger

experience . Int J Radiat Oncol Biol Phys 2003 ; 57 : 944 – 952 . 6 Lotan Y Roehrborn CG . Clearance rates of total prostate specific antigen (PSA) after radical prostatectomy in African-Americans and Caucasians .. Prostate Cancer Prostatic

Full access

New Developments in the Management of Prostate Cancer

Philip W. Kantoff and James L. Mohler

.77 P = .02) despite a 50% crossover rate; however, time to disease progression was similar to that of control patients. 5 Interestingly, patients with lower prostate-specific antigens (PSAs) appear to benefit more than those with advanced disease

Full access

Use of Nomograms for Early Detection in Prostate Cancer

Devon C. Snow and Eric A. Klein

available for metastatic prostate cancer, treatment can be curative if it is caught early. The goal of early diagnosis and radical treatment was first suggested in 1905. 2 The introduction of prostate-specific antigen (PSA) as a screening tool in the late

Full access

Point/Counterpoint: Early Detection of Prostate Cancer: Do the Benefits Outweigh the Consequences?

Peter R. Carroll and Andrew J. Vickers

center of the debate is the question of whether the benefits of prostate-specific antigen (PSA) screening (namely the reduction in mortality) outweigh the harms (overdiagnosis and overtreatment). According to Dr. Vickers and his colleague Peter R. Carroll

Full access

The Selection of Hormonal Therapy in Prostate Cancer: Who, When, and for How Long?

Charles J. Ryan and Eric J. Small

Strawderman MS . Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer . J Clin Oncol 1998 ; 16 : 1835 – 1843 . 9 Sartor O Weinberger M Moore A . Effect of prednisone on

Full access

The Prostate Cancer Risk Stratification Project: Database Construction and Risk Stratification Outcome Analysis

George Rodrigues, Himu Lukka, Padraig Warde, Michael Brundage, Luis Souhami, Juanita Crook, Fabio Cury, Charles Catton, Gary Mok, Andre-Guy Martin, Eric Vigneault, Jim Morris, Andrew Warner, Sandra Gonzalez Maldonado, Tom Pickles, and the Genitourinary Radiation Oncologists of Canada (GUROC)

AJCC T1-T2a, prostate-specific antigen (PSA) ≤10 ng/mL, and Gleason score ≤6 Intermediate-risk: 1997 AJCC T1-T2, PSA ≤20 ng/mL, and Gleason score ≤7 not otherwise low-risk High-risk: 1997 AJCC T3-T4 or PSA >20 ng/mL, or Gleason score 8-10 The

Full access

Prostate Biopsy Strategies: Current State of the Art

Badar M. Mian

most out of six systematic sextant biopsies . Urology 1995 ; 45 : 2 – 12 . 4 Catalona WJ Richie JP Ahmann FR . Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results

Full access

Appropriate Use of Nomograms to Guide Prostate Cancer Treatment Selection

Andrew K. Lee and Christopher L. Amling

Subong EN . Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update . JAMA 1997 ; 277 : 1445 – 1451 . 2. D'Amico AV Whittington R

Full access

Use of Circulating Tumor DNA for the Clinical Management of Metastatic Castration-Resistant Prostate Cancer: A Multicenter, Real-World Study

Baijun Dong, Liancheng Fan, Bin Yang, Wei Chen, Yonghong Li, Kaijie Wu, Fengbo Zhang, Haiying Dong, Huihua Cheng, Jiahua Pan, Yinjie Zhu, Chenfei Chi, Liang Dong, Jianjun Sha, Lei Li, Xudong Yao, and Wei Xue

were collected by the lead investigators at each site. Progression-free survival (PFS) was defined as the time from the date of treatment initiation to confirmed prostate-specific antigen (PSA) increase, clinical or radiographic progression, or death